Help your HoFH patients Knock down extremely high LDL-C levels
EVKEEZA® cut LDL-C by ~50% at 24 weeks regardless of background therapy in combination with low-fat diet and other LDL-C lowering therapies1*
Study R1500-CL-1629 (ELIPSE-HoFH) Phase 3 study in 65 patients aged ≥ 12 years with HoFH
(49% reduction in LDL-C: LS mean treatment difference: 95% CI: -65% to -33%; P<0.0001 or -3.4 mmol/L absolute change from placebo; 95% CI: -4.5 to -2.3; P<0.0001)1,2
learn moreStudy R1500-CL-17100 Phase 3, Part B, open-label study conducted in 14 patients aged ≥ 5 to 11 years with HoFH
(48% reduction in LDL-C or -3.41 mmol/L from baseline;
95% CI: -69% to -28%)1,3
Homozygous familial hypercholesterolemia (HoFH) is characterized by extremely elevated LDL-C.2
Innovation
EVKEEZA is the first and only approved ANGPTL3 inhibitor that lowers LDL-C independently of LDLR activity1
Efficacy
Safety
EVKEEZA has a demonstrated safety profile2
The most common adverse reactions include nasopharyngitis, influenza-like illness, dizziness, back pain, and nausea. Fatigue was identified as an adverse reaction for pediatric patients 5 to 11 years of age only.
HoFH=homozygous familial hypercholesterolemia; LDL-C=low-density lipoprotein cholesterol; ANGPTL3=angiopoietin-like 3; LDLR=LDL-receptor.
References:
- EVKEEZA Product Monograph, Ultragenyx Pharmaceutical, Inc. 2025.
- Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711-720.
- Wiegman A, et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. Circulation. 2024;149(5):343-353.
